First-in-Human Drug Trials: How Is Risk Reduced?

How do researchers choose the first human dose?

Before a new medicine reaches its first volunteers, investigators must translate laboratory findings into a defensible human starting dose. FDA guidance for studies in healthy adults describes an approach that begins with animal doses without observed adverse effects, converts those findings into human-equivalent doses and applies a safety factor. Researchers also consider which animal model best represents the medicine's effects in humans. These calculations require scientific judgment because species can differ in sensitivity, metabolism and drug exposure. [FDA starting-dose guidance](https://www.fda.gov/files/drugs/published/Estimating-the-Maximum-Safe-Starting-Dose-in-Initial-Clinical-Trials-for-Therapeutics-in-Adult-Healthy-Volunteers.pdf)

The resulting estimate is a maximum recommended starting dose; investigators may begin lower. The guidance also calls for consideration of the dose expected to produce biological activity and the medicine's broader toxicity profile. Its scope matters: this framework addresses healthy adult volunteers and does not establish starting doses for patients, including those receiving potentially toxic cancer therapies. Consequently, a dosing calculation appropriate for one development program cannot automatically be transferred to another.

Why are the first participants sometimes dosed separately?

The European Medicines Agency describes sentinel dosing as giving the investigational medicine to one participant before the rest of a dosing group. In a placebo-controlled trial, one participant may receive the active medicine while another receives placebo. Investigators then review the available findings before proceeding. The strategy limits how many people are exposed before the first human safety observations become available. Departures from this approach should have a scientific justification proportionate to the risks. [EMA early-trial safety guidance](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-and-mitigate-risks-first-human-and-early-clinical-trials-investigational-medicinal-products-revision-1_en.pdf)

The observation interval depends on how the medicine moves through the body, how long its effects last and the uncertainties surrounding it. Progression also requires predefined stopping rules and review of accumulating safety information. These safeguards reduce exposure to emerging hazards, but cannot eliminate unexpected or delayed adverse effects. This European guidance provides a safety framework; it does not establish the requirements of China's accelerated pathway.

What should people understand before joining an early drug trial?

The FDA describes Phase 1 studies as typically involving 20–100 healthy volunteers or people with the condition under investigation, with safety and dosage as central objectives. Actual enrollment varies by protocol. These studies investigate how a drug behaves in people and which adverse effects emerge as exposure changes. Authorization to conduct a trial therefore does not establish that the medicine improves health outcomes or is approved for routine prescribing. Early safety findings help determine whether and how development should continue. [FDA clinical research overview](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research)

Informed consent should give prospective participants enough information and time to decide freely. FDA guidance addresses explaining experimental procedures, reasonably foreseeable risks, potential benefits and appropriate alternatives. Practical questions include whom to contact about symptoms, what costs participation could involve and how withdrawal would be managed. Significant new information that could affect willingness to continue also needs to be communicated. These US consent requirements illustrate why an efficient regulatory review cannot substitute for a careful conversation with each prospective participant. [FDA informed-consent guidance](https://www.fda.gov/media/88915/download)